Inactive Instrument

Highlights Therapix Biosciences Ltd TEL AVIV STOCK EXCHANGE

Equities

TRPX

IL0010951403

End-of-day quote TEL AVIV STOCK EXCHANGE Other stock markets
- ^ILS	-

03/06	SciSparc Ltd. Secures Strategic Advantage with Grant of European Patent	CI
11/04	SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

SciSparc Ltd. Secures Strategic Advantage with Grant of European Patent	03/06	CI
SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd.	11/04	CI
Tranche Update on SciSparc Ltd.'s Equity Buyback Plan announced on July 7, 2022.	02/04	CI
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
SciSparc Ltd. Receives Another Patent, Strengthening its Core Technology in Canada	18/03	CI
SciSparc Ltd. Announces Successfully Dosed the First Patient in Its SCI-210 Clinical Trial At the Soroka Medical Center for Pediatric Patients	14/03	CI
SciSparc Ltd. Announces Enrollment of First Patient for Its Clinical Trial for Children with Autism Spectrum Disorder	08/03	CI
Scisparc Ltd. Granted Patent for Core Technology in Multiple Jurisdictions in Europe	07/03	CI
SciSparc Ltd. Receives Canadian Patent for Opioids Reduction Use in Pain Management Technology	07/03	CI
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing	29/02	CI
Clearmind Medicine Submits Three International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds	27/02	MT
Clearmind Medicine Submits Three International Patent Applications for Next Generation Psychedelic-Based Compounds	20/02	MT
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder	29/01	CI
SciSparc Ltd. and Clearmind Medicine Inc. Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments	04/01	CI
Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial	01/12	CI
SciSparc Ltd. Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment	28/11	CI
SciSparc Signs Letter of Intent to Merge With Vehicle Importer in Israel	22/11	MT
An unknown buyer signing of a non-binding letter of intent to acquire SciSparc Ltd. in reverse merger transaction.	22/11	CI
SciSparc Ltd. Unveils Positive Topline Results from its Investigator-Initiated Phase IIa Trial At the Sophie & Abraham Stuchynski Israeli Alzheimer's Medical Center	15/11	CI
SciSparc Ltd. Announces Initiation of its Phase IIb Clinical Trial Treatments with its SCI-110, Proprietary Drug Candidate	10/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Therapix Biosciences Ltd TEL AVIV STOCK EXCHANGE

Equities

TRPX

IL0010951403

Highlights

Filters